The human proteome - A scientific opportunity for transforming diagnostics, therapeutics, and healthcare

Clinical Proteomics

Volumn 9, Issue 1, 2012, Pages

  Vidal, Marc ^a   Chan, Daniel W ^b   Gerstein, Mark ^c   Mann, Matthias ^d   Omenn, Gilbert S ^e   Tagle, Danilo ^f   Sechi, Salvatore ^g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e UNIVERSITY OF MICHIGAN   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEOME;

ALTERNATIVE RNA SPLICING; BIOINFORMATICS; BREAST CANCER; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL PRACTICE; CONFERENCE PAPER; CRYSTAL STRUCTURE; DIAGNOSTIC TEST; DYNAMICS; EPIGENETICS; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOME; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE MAP; HEALTH CARE; HEALTH CARE NEED; HUMAN; MASS SPECTROMETRY; MEDICAL RESEARCH; METABOLOMICS; NEOPLASM; PATIENT CARE; PHENOTYPE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LIPID INTERACTION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; RNA ANALYSIS; RNA SPLICING; SELECTED REACTION MONITORING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; WORKSHOP;

EID: 84902160831     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-9-6     Document Type: Conference Paper

References (34)

1. Uhlen M, et al: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010, 28(12):1248-1250.
2. Picotti P, et al: High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods 2010, 7(1):43-46.
3. Legrain P, et al: The human proteome project: Current state and future direction. Mol Cell Proteomics 2011, 10(7): 009993.
4. Uhlén M, et al: Antibody-based protein profiling of the human chromosome 21. Mol Cell Proteomics 2011, 11(3): 013458.
5. Schwanhäusser B, et al: Global quantification of mammalian gene expression control. Nature 2011, 473(7347):337-342.
6. Beck M, et al: The quantitative proteome of a human cell line. Mol Syst Biol 2011, 7:549.
7. Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J, Pääbo S, Mann M: Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol 2011, 7:548.
8. Vidal M, Cusick ME, Barabási AL: Interactome networks and human disease. Cell 2011, 144(6):986-998.
9. Spencer SL, Sorger PK: Measuring and modeling apoptosis in single cells. Cell 2011, 144(6):926-939.
10. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK: Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009, 459(7245):428-432.
11. Stark C, et al: The Bio GRID Interaction Database: 2011 update. Nucleic Acids Res 2011, 39:D698-D704.
12. Kim PM, Korbel JO, Gerstein MB: Positive selection at the protein network periphery: evaluation in terms of structural constraints and cellular context. Proc Natl Acad Sci USA 2007, 104(51):20274-20279.
13. Bhardwaj N, Abyzov A, Clarke D, Shou C, Gerstein MB: Integration of protein motions with molecular networks reveals different mechanisms for permanent and transient interactions. Protein Sci 2011, 20(10):1745-1754.
14. Balasubramanian S, et al: Gene inactivation and its implications for annotation in the era of personal genomics. Genes Dev 2011, 25(1):1-10.
15. Howe D, et al: Big data: The future of biocuration. Nature 2008, 455(7209):47-50.
16. Park Y, Moore C, Bader JS: Dynamic networks from hierarchical bayesian graph clustering. PLoS One 2010, 5(1):e8118.
17. Menon R, Roy A, Mukerjee S, Belkin S, Zhang Y, Omenn GS: Functional implications of structural predictions for alternative splice proteins expressed in Her2/neu-induced breast cancers. J Proteome Research 2011, 10(12):5503-5511.
18. Consortium Uni Prot: Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res 2011, 39:D214-D219.
19. De Godoy LM, et al: Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast. Nature 2008, 455 (7217):1251-1254.
20. Nagaraj N, Mann M: Quantitative analysis of the intra- And inter-individual variability of the normal urinary proteome. J Proteome Res 2011, 10(2):637-645.
21. Tran JC, et al: Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 2011, 480(7376):254-258.
22. Graumann J, Scheltema RA, Zhang Y, Cox J, Mann M: A framework for intelligent data acquisition and real-time database searching for shotgun proteomics. Mol Cell Proteomics 2012, 11(3): 013185.
23. Kuhn E, et al: Inter-laboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics 2011, 111.013854.
24. Phanstiel DH, et al: Proteomic and phosphoproteomic comparison of human ES and iPS cells. Nat Methods 2011, 8(10):821-7.
25. Geiger T, Cox J, Mann M: Proteomic changes resulting from gene copy number variations in cancer cells. PLoS Genet 2010, 6(9):e1001090.
26. Zhong Q, et al: Edgetic perturbation models of human inherited disorders. Mol Syst Biol 2009, 5:321.
27. Farrah T, et al: A high-confidence human plasma proteome reference set with estimated concentrations in Peptide Atlas. Mol Cell Proteomics 2011, 10(9): 110-006353.
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006, 100(2):229-35. (Pubitemid 44631925)
29. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 2008, 100(20):1432-8.
30. Chan DW: Will cancer proteomics suffer from premature death? Clinical Proteomics 2010, 6:1-3.
31. Zhang Z, Chan DW: The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010, 19:2995-9.
32. Sturgeon CM, et al: Taking a new biomarker into routine use - A perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010, 4:892-903.
33. Hood L, Friend SH: Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011, 8(3):184-7.
34. Venkatesan K, et al: An empirical framework for binary interactome mapping. Nat Methods 2009, 6(1):83-90.